Avenue Therapeutics Shares Jump 30% on FDA Meeting Minutes
By Denny Jacob
Avenue Therapeutics Inc. shares jumped 30% to $1.49 in aftermarket trading Monday after receiving minutes from a meeting with the Food and Drug Administration, which it said indicated that the two sides are in agreement with a majority of proposals and are in active discussions about remaining open items.
The specialty pharmaceutical company in March participated in a Type C meeting with the Food and Drug Administration on Thursday regarding a study assessing risks related to opioid stacking.
"We are finalizing the protocol based on the FDA's feedback and look forward to the continued collaborative discussions with the FDA with the goal of partnering or initiating a Phase 3 safety study this year," said Chief Executive Alexandra MacLean.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 17, 2023 16:36 ET (20:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month